331 related articles for article (PubMed ID: 24963042)
1. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
Rondelli D; Goldberg JD; Isola L; Price LS; Shore TB; Boyer M; Bacigalupo A; Rambaldi A; Scarano M; Klisovic RB; Gupta V; Andreasson B; Mascarenhas J; Wetzler M; Vannucchi AM; Prchal JT; Najfeld V; Orazi A; Weinberg RS; Miller C; Barosi G; Silverman LR; Prosperini G; Marchioli R; Hoffman R
Blood; 2014 Aug; 124(7):1183-91. PubMed ID: 24963042
[TBL] [Abstract][Full Text] [Related]
2. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.
Keyzner A; Han S; Shapiro S; Moshier E; Schorr E; Petersen B; Najfeld V; Kremyanskaya M; Isola L; Hoffman R; Mascarenhas J
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2180-2186. PubMed ID: 27596130
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
5. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
[TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
[TBL] [Abstract][Full Text] [Related]
8. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Jain T; Kunze KL; Temkit M; Partain DK; Patnaik MS; Slack JL; Khera N; Hogan WJ; Roy V; Noel P; Leis JF; Sproat LZ; Fauble V; Mesa RA; Palmer J
Bone Marrow Transplant; 2019 Feb; 54(2):204-211. PubMed ID: 29795431
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
10. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
11. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
12. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
[TBL] [Abstract][Full Text] [Related]
13. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Patriarca F; Masciulli A; Bacigalupo A; Bregante S; Pavoni C; Finazzi MC; Bosi A; Russo D; Narni F; Messina G; Alessandrino EP; Carella AM; Milone G; Bruno B; Mammoliti S; Bruno B; Fanin R; Bonifazi F; Rambaldi A;
Biol Blood Marrow Transplant; 2019 May; 25(5):932-940. PubMed ID: 30579966
[TBL] [Abstract][Full Text] [Related]
14. Outcome of transplantation for myelofibrosis.
Ballen KK; Shrestha S; Sobocinski KA; Zhang MJ; Bashey A; Bolwell BJ; Cervantes F; Devine SM; Gale RP; Gupta V; Hahn TE; Hogan WJ; Kröger N; Litzow MR; Marks DI; Maziarz RT; McCarthy PL; Schiller G; Schouten HC; Roy V; Wiernik PH; Horowitz MM; Giralt SA; Arora M
Biol Blood Marrow Transplant; 2010 Mar; 16(3):358-67. PubMed ID: 19879949
[TBL] [Abstract][Full Text] [Related]
15. Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
Leuk Lymphoma; 2012 Jan; 53(1):162-5. PubMed ID: 21756024
[No Abstract] [Full Text] [Related]
16. Fludarabine/Melphalan 100 mg/m
Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
[TBL] [Abstract][Full Text] [Related]
17. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
18. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
19. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kröger N; Holler E; Kobbe G; Bornhäuser M; Schwerdtfeger R; Baurmann H; Nagler A; Bethge W; Stelljes M; Uharek L; Wandt H; Burchert A; Corradini P; Schubert J; Kaufmann M; Dreger P; Wulf GG; Einsele H; Zabelina T; Kvasnicka HM; Thiele J; Brand R; Zander AR; Niederwieser D; de Witte TM
Blood; 2009 Dec; 114(26):5264-70. PubMed ID: 19812383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
